Clinical Trials Directory

Trials / Recruiting

RecruitingNCT03811171

Break Wave(TM) Extracorporeal Lithotripter First-in-Human Study

A Study of the SonoMotion Break Wave(TM) System for the Comminution of Urinary Tract Stones

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
70 (estimated)
Sponsor
SonoMotion · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a prospective, open-label, multi-center, single-arm (non-randomized) study to assess the safety and effectiveness of breaking stones in the upper urinary tract using the SonoMotion Break Wave technology. Up to 30 subjects will be included. The procedure will be performed in a hospital surgical environment as an outpatient (without being admitted) or in a non-surgical environment such as a clinic or office procedure room. The procedure will be performed under varying levels of anesthesia ranging from no anesthesia to general anesthesia (fully asleep). Stones will be limited to ≤ 10 mm for lower pole stones and ≤ 20 mm everywhere else. Safety will be measured by the self-reported occurrences of adverse events, unplanned emergency department or clinic visits, and the need for further intervention. Fragmentation will be measured by self-reported stone passage and a comparison of computed tomography (CT) images before and after the procedure.

Conditions

Interventions

TypeNameDescription
DEVICEBreak Wave extracorporeal lithotripsyThe Break Wave device will be used to exert a low amplitude burst of ultrasound waves focused at the kidney stone. The primary components of the device include an 85 mm aperture diameter therapy probe driven by a high voltage generator. The therapy probe has a cavity in the middle to accommodate coaxial alignment of an ultrasound imaging probe for treatment guidance.

Timeline

Start date
2019-08-20
Primary completion
2027-01-30
Completion
2027-03-30
First posted
2019-01-22
Last updated
2025-07-29

Locations

6 sites across 2 countries: United States, Canada

Regulatory

Source: ClinicalTrials.gov record NCT03811171. Inclusion in this directory is not an endorsement.

Break Wave(TM) Extracorporeal Lithotripter First-in-Human Study (NCT03811171) · Clinical Trials Directory